teva pharmaceuticals ltd (1)==
DESCRIPTION
Teva PharmaTRANSCRIPT
![Page 1: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/1.jpg)
TEVA PHARMACEUTICALS
P. Balakrishna Pawan Malik Poorimitla Brahmaiah Prateek Gupta Rahul Duggar
![Page 2: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/2.jpg)
“
”
We LEAD THE WAY. We are committed to EXCELLENCE We are prepared for CHANGE We are
ACCESSIBLE We value
SIMPLICITY
We are ONE TEVA
![Page 3: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/3.jpg)
Agenda
Industry Introduction
About Teva
Mergers and Acquisitions
Options for growth
Geography wise analysis of Teva
Strategic Analysis
Financial Analysis
Conclusion
![Page 4: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/4.jpg)
Introduction
![Page 5: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/5.jpg)
Overview of the Pharmaceutical Industry
Worldwide pharmaceutical industry – $ 600B
Total companies – 600
Industry capitalization – 1.5 T
Growth rate over the last 5 years – 12%
ROE – 20% (highest of any industry).
![Page 6: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/6.jpg)
Topics/terms to be covered
New drug product development by innovators
Generic drug product development
Para IV challenge and its impact
Bio-similars
Niche markets
Compulsory licensing
![Page 7: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/7.jpg)
New Drug Product development Process - INNOVATORS
![Page 8: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/8.jpg)
New Drug Product development Process - GENERICS
![Page 9: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/9.jpg)
Para IV Challenge
![Page 10: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/10.jpg)
Issues facing pharmaceutical industry
Innovators
Pharmaceutical research is a high risk activity
Strong regulatory framework – market entry barrier
Sales and marketing sales are huge
Drugs are losing patent protection
Life cycle of the drugs are facing competition from the generics.
Growth rate is slowing down
Few molecules are being approved
Generics
Fierce competition
Lack of expertise to develop niche and biosimilar products
Lack of capital
![Page 11: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/11.jpg)
About Us
![Page 12: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/12.jpg)
History
Birth of company in Jerusalem in 1901
Distributed imported medications.
Raised capital through an initial public offering on the Tel Aviv Stock Exchange in 1951
Merger of 3 biggest local companies to form Teva Pharmaceutical Industries Ltd in 1976
Entered the US market in the 1980s
![Page 13: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/13.jpg)
Competitors
Sandoz – Generics arm of Novatris
Pfizer
Merck
Low cost players from emerging markets ( Ranbaxy, Dr. Reddy’s , Pliva, Aegis etc.)
![Page 14: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/14.jpg)
Mergers and Aquisitions
![Page 15: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/15.jpg)
Criteria for acquisitions
![Page 16: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/16.jpg)
Acquisitions by Teva
Teva is global – political risk is thus diversified.
establishing a stronger, more competitive company with increased scale and
an expanded geographic footprint with significant potential for growth
Ivax Corporation, Dynamic company – No 1 Generic player
Sicor, enhance and expand the combined company's product offerings (biogenerics capabilities)
Novopharm Ltd, second largest generic drug company with operations in the United States and Hungary
WR Grace Ltd, – Increase in US market share
IkaPharm, –FDA approved plant, entry to US
![Page 17: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/17.jpg)
Teva Acquisitions from 1985-2005 (Exhibit 3)
![Page 18: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/18.jpg)
Acquisition till date
![Page 19: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/19.jpg)
Options for Growth
![Page 20: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/20.jpg)
Where to grow
Grow in the generics market
Gradually turn into more specialized generics or innovative firm
Focus on all the three areas – Generics, Innovative and Biosimilars
![Page 21: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/21.jpg)
How to grow
Growth through market leadership
External environment
Core strengths and competitive advantage
value proposition
Product portfolios.
Go- to- market initiatives
Customer centric business model
Entering into emerging economies
Identity in Developed economies
Balanced business model.
![Page 22: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/22.jpg)
![Page 23: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/23.jpg)
![Page 24: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/24.jpg)
![Page 25: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/25.jpg)
Geography wise analysis
![Page 26: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/26.jpg)
Geographies
United States
Western/ Eastern Europe
Japan
Latin America
Asia
![Page 27: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/27.jpg)
Teva Revenues By Region (2004)
64%
26%
6%
4%
North AmericaEuropeIsraelRest of the World
![Page 28: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/28.jpg)
Teva Revenues By Region (2008)
5825
4
13
North AmericaEuropeIsraelRest of the World
![Page 29: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/29.jpg)
Strategic Analysis
![Page 30: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/30.jpg)
TOWS Analysis
EXTERNAL
INTERNAL
Opportunities1. Demographic Trends2. Health care reforms3. Emerging Markets
Threats1. Political situation in the parent
country2. Threat of new entrants3. New drugs more competitive
than Teva products
Strengths1. Largest generic drug
maker in the world2. Good with M & A3. Flexible4. Less R & D costs as
compared to competitors5. Low cost supply chain6. APIs
ADVANCEMENT
Further expand into global branded generics market
AVOID THREATS
Turn into a more specialized generics or innovative firm
Weaknesses1. Drugs coming off patents2. Weak in physician driven
markets like Germany & Japan
3. High Debts
OVERCOME WEAKNESS
Focus on generic, biosimilars and innovative drug markets
AVOID AND OVERCOME
Focus more on the domestic markets
![Page 31: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/31.jpg)
Value Chain Analysis
Primary Activities
Operations
Direct operations in over 50 markets in Americas, Israel, Europe and Asia
36 pharmaceuticals manufacturing sites, 16 API sites, 17 generic R&D centers
Operates in two segments: pharmaceuticals and active pharmaceuticals ingredients(API)
![Page 32: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/32.jpg)
Outbound Logistics
Operates through its international product division in other countries
Sales are through direct exports from Israel and other manufacturing sites.
Ivax has subsidiaries in South and Latin American countries where they sells branded non-proprietary products.
Service
Leading non-governmental supplier of health care products and services in Israel.
Markets generic pharma, OTC, consumer health care products, hospital supplies, etc.
Involved in marketing, sales and distribution of a range of healthcare products and services for generic market.
![Page 33: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/33.jpg)
Marketing & Sales
Well organized and effective marketing channels. Sales in US were made through drug store chains (45%), drug wholesalers (27%), generic distributors (5%), managed care organizations (14%), hospitals and affiliated organizations (9%).
A critical window exists between when a proprietary product loses its patent and generic manufacturer gets their product approved. Knowledgeable sales forces, strong relationship with physicians as well as integrated marketing communications are necessary to grab and maintain a strong position.
Teva’s network of hospitals and institutional channels for generic intravenous products.
![Page 34: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/34.jpg)
Support Activities
Procurement and Technological Development
Involved in innovation research and development for over two decades. Progress in Central nervous system and auto immune diseases. Copaxone and Azilect were products out of this research.
Acquisition of companies like Sicor strengthened its expertise in chemistry of steroids and high-potency production. Ivax provided Teva’s API division with additional 30 APIs and access to new technologies.
![Page 35: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/35.jpg)
PESTLE Analysis
Issue Impact On BusinessPolitical
Growing political focus and pressure on healthcare
Governments looking for healthcare savings Harmonization of healthcare across Europe
More pressure on pricing and cut backs Reference pricing, exposing price across
borders
Economic
Global economic crisis Reduction in individual disposable income Increasing pressure on pricing by different
buying groups Reduction in pharmaceutical growth
Reluctance of consumers to spend on healthcare
Need to introduce value adding processes Increased pressure from shareholders Increased pressure on pricing
![Page 36: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/36.jpg)
PESTLE Analysis (Contd…)Social/Cultural
Patient awareness, changing expectations Increasing age of population Patient/public activism
More pressure on customer service Better intelligence gathering required. Market growth with increasing health
concerns
Technological
After the mapping of the human genome there was much hype about the possibilities for genetic research in pharmaceuticals
Customized treatment
Direct to patient communication More responsive service facilities required
![Page 37: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/37.jpg)
PESTLE Analysis (Contd…)
Legislation
Changes in advertising laws Increased litigations Global inconsistencies
Need to focus on education Quality becomes key
Environmental
Growing environmental agenda and awareness
Identify eco opportunities to market
![Page 38: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/38.jpg)
Financial Analysis
![Page 39: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/39.jpg)
Financial Interpretation of TEVA
Revenue
Research & Development Expenses
Cash & Other Receivables
Patents & Other Intangibles
Goodwill
Current Liabilities
Equity Stock
![Page 40: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/40.jpg)
Excerpts from 2005 Annual Report
![Page 41: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/41.jpg)
Excerpts from 2005 Annual Report
![Page 42: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/42.jpg)
![Page 43: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/43.jpg)
A Future Financial Snapshot2010 2009 2008 2007 2006
NET SALES 16 121 13 899 11 085 9 408 8 408
GROSS PROFIT 9 065 7 367 5 968 4 877 4 259
OPERATING INCOME 3 871 2 405 1 145 2 395 796
RESEARCH AND DEVELOPMENT 933 802 786 581 495
![Page 44: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/44.jpg)
Case writer estimates
![Page 45: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/45.jpg)
Case writer estimates
![Page 46: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/46.jpg)
![Page 47: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/47.jpg)
Credit ratings
A - A3
![Page 48: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/48.jpg)
Conclusion
![Page 49: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/49.jpg)
Market wise
![Page 50: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/50.jpg)
In USA
Market Size $bn;2010 Generics Penetration % ( Volume )
312
96
45
22
75%
23%
68%
63%
![Page 51: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/51.jpg)
Generics market in US
Accounts for maximum share of sales in generic drugs
Good at filing ANDA in USA and Paragraph IV exclusivity period provides higher margins
Debt crisis in Europe has made Europe an unattractive market
People in US looking to cut costs and Teva specializes in low cost drugs
![Page 52: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/52.jpg)
In Europe
Market Size $bn;2010 Generics Penetration % ( Volume )
312
96
45
22
75%
23%
68%
63%
![Page 53: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/53.jpg)
Biosimilars and Niche markets in Europe
Less competitive in generics
Higher entry barriers
Price erosion with generic markets in the US
Important to get in the European market before competitors
![Page 54: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/54.jpg)
In Japan
Market Size $bn;2010 Generics Penetration % ( Volume )
312
96
45
22
75%
23%
68%
63%
![Page 55: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/55.jpg)
Parternships / JVs
High growth generic market
Physician driven markets
Lack of experience in this market
Take it slow and start with partnership / joint ventures with generic drug manufacturers
![Page 56: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/56.jpg)
Product Wise
![Page 57: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/57.jpg)
Develop Generics Market
Increased opportunities in emerging generic markets
People living longer and consuming more drugs
Helathcare reforms and cost saving initiatives
$150 bn of brands going off patent in the next years
![Page 58: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/58.jpg)
Develop Biosimilars Market
http://www.dvfa.de/files/die_dvfa/kommissionen/life_science/application/pdf/6_Frank_Pieters_Teva.pdf
90% of the Biotechnology drugs to go off patent till 2020
All Biologics
Patents expiring 2016-2020
Patents expiring 2010-2015
Patents expired 2009 or earlier
![Page 59: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/59.jpg)
Develop Innovative drugs market
Great success with Copaxone. It’s a blockbuster drug
R & D costs are much lower than competitors
Strong competetion from low cost players from the emerging markets. For eg Ranbaxy from India
Innovative drug companies entering generic drug market
Large opportunity in this sector in the future.
![Page 60: Teva Pharmaceuticals Ltd (1)==](https://reader030.vdocuments.mx/reader030/viewer/2022020715/545aae4faf79594e128b56ff/html5/thumbnails/60.jpg)
Recommendations
Healthcare industry is changing and Teva needs to adapt and grow accordingly
Needs to follow a balanced business strategy
Expand leadership in key markets like Japan and other emerging markets